Where to deploy pre-exposure prophylaxis(prep) in sub-saharan Africa

Sexually Transmitted Infections

Volumn 89, Issue 8, 2013, Pages 628-634

  Verguet, Steańphane ^a   Stalcup, Meg ^a,b   Walsh, Julia A ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; ARTICLE; CIRCUMCISION; COMPARTMENT MODEL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EXPOSURE; HETEROSEXUAL MALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICATION COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMALIA; VIRUS TRANSMISSION; ADOLESCENT; ADULT; ATTITUDE TO HEALTH; CHEMOPROPHYLAXIS; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; FEMALE; HIV INFECTIONS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRIMARY PREVENTION; PROCEDURES; SEXUAL BEHAVIOR; STATISTICS AND NUMERICAL DATA; TRANSMISSION;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CHEMOPREVENTION; CIRCUMCISION, MALE; COST-BENEFIT ANALYSIS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HETEROSEXUALITY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRIMARY PREVENTION; SEXUAL BEHAVIOR;

EID: 84891840672     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2012-050891     Document Type: Article

References (34)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva: UNAIDS, 2010.
2. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in Sub-Saharan Africa: A systematic review and meta-analysis. AIDS 2000;14:2361-70.
3. WHO, UNAIDS, UNICEF. Global HIV/AIDS response: Epidemic update and health sector progress toward universal access: Progress report 2011. Geneva: World Health Organization, 2011.
4. Attia S, Egger M, Müller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy. AIDS 2009;23:1397-404.
5. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: A prospective cohort analysis. Lancet 2010;375:2092-8.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74.
8. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprohylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
9. Baeten J, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
10. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-34.
11. van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012;26:F13-19.
12. http://www.mtnstophiv.org/news/studies/mtn003 (accessed 23 May 2012).
13. Johnson LF, White PJ. A review of mathematical models of HIV/AIDS interventions and their implications for policy. Sex Transm Infect 2011;87:629-34.
14. Vissers DCJ, Voeten HACM, Nagelkerke NJD, et al. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: A simulation study. PloS ONE 2008;3:e2077.
15. Pretorius C, Stover J, Bollinger L, et al. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PloS ONE 2010;5:e13646.
16. Abbas U, Anderson R, Mellors J. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PloS ONE 2007;2:e875.
17. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: A modelling study. PloS Med 2011;8:e1001123.
18. Menzies NA, Berruti AA, Berzon R, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 2011;25:1753-60.
19. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191:1403-9.
20. Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission (Review). Cochrane Database Syst Rev 2002;(1):CD003255.
21. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 Trial. PloS Med 2005;2:e298.
22. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America, a meta-analysis. JAMA 2006;296:679.
23. United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: The 2010 revision. New York: United Nations, 2011.
24. Williams BG, Lloyd-Smith JO, Gouws E, et al. The potential impact of male circumcision on HIV in sub-Saharan Africa. PloS Med 2006;3:e262.
25. Eligibility for ART in lower income countries collaboration. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: Collaborative analysis of prospective studies. Sex Transm Infect 2008;84:i31.
26. Stringer JSA, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296:782-93.
27. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 2002;22:475-81.
28. Shisana O, Rehle T, Simbayi LC, et al. South African national HIV prevalence, incidence, behaviour, and communication survey 2008: A turning tide among teenagers? Cape Town: HSRC Press, 2009.
29. World Bank. World development indicators. Washington, DC: The World Bank, 2012. http://data.worldbank.org/data-catalog/world-development-indicators (accessed 20 Nov 2012).
30. World Health Organization. Macroeconomics and health: Investing in health for economic development. Report of the commission on macroeconomics and health. Geneva: World Health Organization; 2001.
31. Bertozzi S, Padian NS, Wegbreit J, et al. HIV/AIDS prevention and treatment. In: Jamison DT, ed. Disease control priorities in developing countries. 2nd edn. New York: Oxford University Press and the World Bank, 2006:331-70.
32. van de Vijver DAMC, Derdelicnkx I, Bouchner CAB. Circulating HIV Type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis 2009;199:1310-17.
33. Foss AM, Hossain M, Vickerman PT, et al. A systematic review of published evidence on intervention impact on condom use in sub-Saharan Africa and Asia. Sex Transm Infect 2007;83:510-16.
34. Kurth AE, Celum C, Baeten JM, et al. Combination HIV prevention: Significance, challenges, and opportunities. Curr HIV/AIDS Rep 2011;8:62-72.